Wall Street analyst estimates for Compugen Ltd. (CGEN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 0 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.86 |
Valuation Ratios
| P/E Ratio | 6.42 |
| Price / Book | 2.57 |
| EV / EBITDA | 6.74 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $712000 | 0 | $17.8M | 0 | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Cost of Revenue | $223000 | $1.6M | $1.0M | $989000 | $60000 | $680000 | $975000 | $2.0M | $7.9M | $9.3M |
| Gross Profit | $489000 | -$1.6M | $16.8M | -$989000 | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Research & Development | $24.5M | $28.6M | $30.3M | $19.8M | $22.8M | $28.7M | $30.6M | $34.5M | $24.8M | $22.8M |
| Selling, General & Admin | $8.5M | $8.8M | $9.7M | $9.1M | $10.7M | $11.7M | $11.3M | $10.0M | $10.0M | $9.4M |
| Operating Expenses | $33.1M | $37.4M | $40.0M | $28.9M | $33.4M | $40.4M | $41.9M | $44.4M | $34.8M | $32.2M |
| Operating Income | -$32.6M | -$37.4M | -$23.2M | -$28.9M | -$31.5M | -$35.1M | -$35.4M | -$13.0M | -$14.9M | $31.3M |
| EBITDA | -$31.1M | -$35.5M | -$21.8M | -$27.0M | -$28.9M | -$33.7M | -$33.1M | -$9.3M | -$9.2M | $35.9M |
| Interest Expense | $705000 | $508000 | $620000 | $32000 | $42000 | $25000 | $27000 | $31000 | $34000 | 0 |
| Pre-tax Income | -$31.5M | -$37.1M | -$22.6M | -$28.1M | -$29.7M | -$34.2M | -$33.6M | -$9.8M | -$9.7M | $35.4M |
| Income Tax | $20000 | 0 | 0 | -$722000 | 0 | 0 | $58000 | $9.0M | $4.5M | $54000 |
| Net Income | -$31.5M | -$37.1M | -$22.6M | -$27.3M | -$29.7M | -$34.2M | -$33.7M | -$18.8M | -$14.2M | $35.3M |
| EPS | $-0.62 | $-0.72 | $-0.41 | $-0.43 | $-0.37 | $-0.41 | $-0.39 | $-0.21 | $-0.16 | $0.38 |
| EPS (Diluted) | $-0.62 | $-0.72 | $-0.41 | $-0.43 | $-0.37 | $-0.41 | $-0.39 | $-0.21 | $-0.16 | $0.38 |
| Shares Outstanding (Diluted) | $50.9M | $51.2M | $55.3M | $63.6M | $79.6M | $84.2M | $86.6M | $87.6M | $89.5M | $93.8M |
Price
| Price | $2.41 |
| Market Cap | $228M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: CRBP · CRDF · CYBN · IPHA · MIST · MOLN · NVCT
Explore sector: Healthcare · Biotechnology
More sections of CGEN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks